Literature DB >> 23099978

Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines.

E Baldini1, S Sorrenti, E D'Armiento, E Guaitoli, S Morrone, V D'Andrea, L Gnessi, C Moretti, A Antonelli, A Catania, E De Antoni, S Ulisse.   

Abstract

OBJECTIVES: Anaplastic thyroid carcinomas (ATC) are highly aggressive tumours unresponsive to any available radio- or chemotherapeutic protocol, with a median survival rate of 4-5 months from the time of diagnosis. We previously demonstrated that ATC are characterized by increased expression of the kinases Aurora-A, -B and -C, involved in the regulation of multiple steps of the mitotic phase. In this study, the in vitro effects of SNS-314 mesylate, a pan-inhibitor of the Aurora kinases, on growth and tumorigenicity of ATC cells were evaluated.
MATERIALS AND METHODS: The effects of SNS-314 mesylate were assessed on the ATC derived cell lines CAL-62, 8305C, 8505C and BHT-101 by means of cell proliferation assay, immunofluorescence, cytofluorimetry, time lapse microscopy, and colony formation in soft agar.
RESULTS: Treatment of the different ATC cells with SNS-314 mesylate inhibited proliferation in a time- and dose-dependent manner, with IC(50) comprised between 2.6 nM and 26.6 nM. CAL-62 cells exposed for 24 h to SNS-314 mesylate 100 nM evidenced a significant augmentation of the apoptotic index. Time-lapse video-microscopy of CAL-62 cells showed that SNS-314 mesylate prevents the completion of mitosis leading to polyploidy. Western blot experiments demonstrated that the auto-phosphorylation of the Aurora kinases as well as histone H3 phosphorylation in CAL-62 treated cells was inhibited. Finally, the drug inhibited colony formation in soft agar of all cell lines.
CONCLUSIONS: Our results demonstrated that SNS-314 mesylate is capable to efficiently reduce cell growth and tumorigenicity of different ATC derived cell lines suggesting its potential therapeutic value for ATC treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23099978

Source DB:  PubMed          Journal:  Clin Ter        ISSN: 0009-9074


  5 in total

Review 1.  The Aurora kinase inhibitors in cancer research and therapy.

Authors:  Jonas Cicenas
Journal:  J Cancer Res Clin Oncol       Date:  2016-03-01       Impact factor: 4.553

Review 2.  Genetics and epigenetics of sporadic thyroid cancer.

Authors:  Dang Vu-Phan; Ronald J Koenig
Journal:  Mol Cell Endocrinol       Date:  2013-08-08       Impact factor: 4.102

3.  Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients.

Authors:  Enke Baldini; Chiara Tuccilli; Natalie Prinzi; Salvatore Sorrenti; Laura Falvo; Corrado De Vito; Antonio Catania; Francesco Tartaglia; Renzo Mocini; Carmela Coccaro; Stefania Alessandrini; Susi Barollo; Caterina Mian; Alessandro Antonelli; Enrico De Antoni; Massimino D'Armiento; Salvatore Ulisse
Journal:  PLoS One       Date:  2015-03-25       Impact factor: 3.240

Review 4.  Functions of Aurora kinase C in meiosis and cancer.

Authors:  Suzanne M Quartuccio; Karen Schindler
Journal:  Front Cell Dev Biol       Date:  2015-08-20

Review 5.  A new aurora in anaplastic thyroid cancer therapy.

Authors:  Enke Baldini; Massimino D'Armiento; Salvatore Ulisse
Journal:  Int J Endocrinol       Date:  2014-07-01       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.